Valproate in Late Life Schizophrenia

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to analyze the effectiveness and tolerability of a medication, valproate ( Depakote and Depakote ER), in individuals age 50 years and older who have schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Collaborator: Abbott
• Treatments: Valproic Acid

Criteria

Inclusion Criteria:

• Must have a diagnosis of schizophrenia as confirmed by the MINI

• Must be on antipsychotic medication

• Must be age 50 year or older

• Must be capable of providing written informed consent for study participation. In situations where individuals have guardians of person, guardian and subject must both provide written consent; and

• Must live in the Northeast Ohio area.

Exclusion Criteria:

• A primary psychiatric DSM Axis I diagnosis other than schizophrenia

• Actively abusing substances; or

• Medically unstable.